Innovent Biologics has announced that its board of directors will convene on Tuesday, 25 August 2026 to review, approve and publish the interim results for the six months ended 30 June 2026.
The notice, released on 10 August 2026, confirms that Chairman and Executive Director Dr. De-Chao Michael Yu will preside over the meeting. Executive Directors Mr. Ronald Hao Xi Ede and Ms. Qian Zhang, along with Independent Non-executive Directors Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Mr. Gary Zieziula, Mr. Shuyun Chen and Dr. Stephen A. Sherwin, will also participate.
The forthcoming meeting will determine the interim financial statements for the first half of 2026 and authorize their release to the market, providing stakeholders with updated insights into the company’s operational and financial performance.